DDInter1381 DDInter927
Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749]
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Paliperidone {u} (Compound) resembles {v} (Compound) Risperidone
Paliperidone {u} (Compound) binds {v} (Gene) DRD2
Paliperidone {u} (Compound) palliates {v} (Disease) schizophrenia
Paliperidone {u} (Compound) causes {v} (Side Effect) Skin discolouration
Paliperidone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Paliperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eribulin
Paliperidone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Paliperidone {u} may lead to a major life threatening interaction when taken with {v} Metoclopramide
Paliperidone {u} may lead to a major life threatening interaction when taken with {v} Vemurafenib
Paliperidone (Compound) resembles Risperidone (Compound)
Paliperidone (Compound) binds DRD2 (Gene)
Paliperidone (Compound) palliates schizophrenia (Disease)
Paliperidone (Compound) causes Skin discolouration (Side Effect)
Paliperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide
Paliperidone may lead to a major life threatening interaction when taken with Metoclopramide
Paliperidone may lead to a major life threatening interaction when taken with Vemurafenib